Wound Care Q Codes 2026: HCPCS Updates and C-Code Deletions

What Changed with Wound Care Q Codes in 2026?

CMS reclassified cellular and tissue-based products (CTPs) -- commonly called skin substitutes -- from individually priced items billed under temporary C-codes to standardized categories billed under permanent Q-codes. This is the largest single change to wound care product billing in over a decade.

The reclassification was not a coverage decision. The same products are still used on the same patients for the same clinical indications. What changed is how they are coded on claims, how they are reimbursed, and which products remain on Medicare's approved list.

If your charge master still contains C-codes for skin substitute products, those claims are denying. This is not a future change -- it took effect January 1, 2026.

Why did CMS delete the C-codes?

CMS created temporary C-codes (the C1xxx and C9xxx series) to track individual skin substitute products while it evaluated long-term payment policy. Each product had its own code and its own ASP-based reimbursement rate, often ranging from $300 to $500+ per square centimeter.

CMS concluded that product-specific pricing created misaligned incentives -- practices were selecting products based on reimbursement margin rather than clinical fit. The reclassification collapses hundreds of product-specific codes into a smaller set of category-based Q-codes, each reimbursed at a flat per-cm² rate of approximately $127.14 regardless of which specific product is applied.

The policy rationale is straightforward: CMS wants to pay for the clinical service, not the brand name.

Which C-codes were deleted?

CMS deleted approximately 250+ temporary C-codes associated with skin substitute products effective January 1, 2026. These include codes that covered products from every major CTP manufacturer -- Organogenesis, MiMedx, Smith+Nephew, Integra LifeSciences, and others.

Examples of deleted codes include:

C1849 -- Skin substitute, synthetic (previously used for products like Integra Dermal Regeneration Template)
C9354 -- Acellular pericardial tissue matrix (used for several bovine pericardial products)
C9356 -- Tendon tissue matrix (used for tendon-derived allografts)
C9358 -- Dermal substitute, native (covered multiple dermal matrix products)
C9360 through C9399 -- A range of product-specific codes that covered individual CTP brands

The full list of deleted codes is published in the CMS HCPCS Quarterly Update files. If you are uncertain whether a specific code you have been billing was deleted, check the January 2026 HCPCS update directly -- do not rely on payer websites, which may lag behind CMS publications.

What are the new Q-codes?

CMS established a set of Q-codes that categorize skin substitutes by product characteristics rather than brand name. The key codes for wound care are:

Q4301 -- Skin substitute, per square centimeter (Category 1: acellular dermal matrix)
Q4302 -- Skin substitute, per square centimeter (Category 2: cellular tissue-based products, human)
Q4303 -- Skin substitute, per square centimeter (Category 3: cellular tissue-based products, synthetic/animal-derived)

Each Q-code is billed per square centimeter applied, and reimbursement is standardized across products within the same category. CMS publishes a product-to-Q-code crosswalk that maps each approved product to its assigned Q-code category.

Not every product that previously had a C-code received a Q-code mapping. Approximately 158 products were dropped from Medicare coverage entirely -- meaning they have no billable HCPCS code under Medicare FFS. Before ordering any skin substitute product, verify that it appears on the current CMS-approved product list and has an assigned Q-code.

What does this mean for my charge master?

Every skin substitute C-code in your charge master needs to be replaced with the corresponding Q-code. This is not optional -- claims submitted with deleted C-codes will deny automatically. There is no grace period.

The charge master update involves three steps:

Identify every deleted C-code in your current charge master.
Map each product to its new Q-code using the CMS product-to-Q-code crosswalk.
Update reimbursement expectations. The old ASP-based rates no longer apply. All products within a Q-code category reimburse at the same flat per-cm² rate.

If your practice uses an EHR or billing system with a code library, verify that the vendor has applied the 2026 HCPCS updates. Some systems require manual code table updates. A billing system that still presents C-codes as valid options is a denial generator.

For a deeper look at the billing workflow changes, see our wound care billing changes guide.

When did these changes take effect?

The reclassification was announced in the CY2026 Medicare Physician Fee Schedule Final Rule, published in November 2025. C-code deletions and Q-code additions took effect January 1, 2026. CMS publishes quarterly HCPCS updates (January, April, July, October) that may add, revise, or delete codes mid-year.

The critical dates:

November 2025: Final Rule published with reclassification details
January 1, 2026: C-codes deleted, Q-codes effective, new reimbursement rates active
Quarterly 2026: Ongoing HCPCS updates may adjust the approved product list or add new Q-codes

Check the CMS HCPCS Quarterly Update page before each quarter to catch any mid-year changes. Products can be added to or removed from the approved list outside the annual rulemaking cycle.

How do I verify current codes?

The authoritative source is the CMS HCPCS code set, available at cms.gov. Specifically:

HCPCS Quarterly Update files for code additions, deletions, and revisions
CMS product-to-Q-code crosswalk for mapping specific products to their assigned Q-code
Medicare Coverage Database for LCD/LCA guidance on documentation and billing requirements associated with the new Q-codes

Do not rely on manufacturer product sheets for billing codes. Several manufacturers continued to reference deleted C-codes in their marketing materials months after the January 2026 effective date. The CMS-published crosswalk is the only authoritative mapping.

What does this mean for LCD compliance?

The Q-code reclassification complicates LCD compliance in two ways.

First, most MACs withdrew their skin substitute-specific LCDs in early 2026, concurrent with the code changes. The documentation requirements -- wound measurements, conservative care trials, vascular assessments -- still apply under general medical necessity standards, but the explicit LCD checklists that practices relied on are no longer published.

Second, the Q-code categories are broader than the old product-specific C-codes. A single Q-code now covers multiple products with different clinical profiles. MAC claims processing systems are adjusting their edit logic to the new code structure, and early reports indicate inconsistent adjudication across jurisdictions.

The practical response: document to the highest standard any MAC has ever required, regardless of which MAC processes your claims. In a post-LCD environment, over-documentation is insurance against denial. For specific LCD compliance strategies, see our LCD compliance reference.

For additional context on the 2026 skin substitute code changes, see our skin substitute Q-code guide and the 2026 wound care billing changes overview.